share_log

啓明醫療-B:2024年第二次非上市外資股類別股東會議通告

VENUS MEDTECH-B: NOTICE OF 2024 SECOND CLASS MEETING OF HOLDERS OFUNLISTED FOREIGN SHARES

HKEX ·  Nov 19, 2024 17:01

Summary by Moomoo AI

啟明醫療-B(VENUS MEDTECH-B)將於2024年12月5日召開2024年第二次非上市外資股類別股東會議。會議將在中國杭州濱江區江陵路88號2幢3樓311室舉行,主要議程包括審議及批准對公司章程第2.07A條的建議修訂,以及其他建議修訂。所有決議案將以投票方式進行表決。股東若欲出席會議,需於2024年11月29日下午4時30分前登記。股東亦可委任代理人出席會議及投票。會議預計需時半日,股東需自理交通及食宿費用。
啟明醫療-B(VENUS MEDTECH-B)將於2024年12月5日召開2024年第二次非上市外資股類別股東會議。會議將在中國杭州濱江區江陵路88號2幢3樓311室舉行,主要議程包括審議及批准對公司章程第2.07A條的建議修訂,以及其他建議修訂。所有決議案將以投票方式進行表決。股東若欲出席會議,需於2024年11月29日下午4時30分前登記。股東亦可委任代理人出席會議及投票。會議預計需時半日,股東需自理交通及食宿費用。
Venus Medtech-B will hold its second non-public foreign shareholder meeting of 2024 on December 5, 2024. The meeting will be held at Room 311, 3rd floor, Building 2, No. 88 Jiangling Road, Binjiang District, Hangzhou, China. The main agenda includes reviewing and approving the proposed amendments to Article 2.07A of the company's articles of association, as well as other proposed amendments. All resolutions will be voted on. Shareholders who wish to attend the meeting must register by 4:30 pm on November 29, 2024. Shareholders may also appoint proxies to attend the meeting and vote. The meeting is expected to last half a day, shareholders are responsible for their own transportation and accommodation expenses.
Venus Medtech-B will hold its second non-public foreign shareholder meeting of 2024 on December 5, 2024. The meeting will be held at Room 311, 3rd floor, Building 2, No. 88 Jiangling Road, Binjiang District, Hangzhou, China. The main agenda includes reviewing and approving the proposed amendments to Article 2.07A of the company's articles of association, as well as other proposed amendments. All resolutions will be voted on. Shareholders who wish to attend the meeting must register by 4:30 pm on November 29, 2024. Shareholders may also appoint proxies to attend the meeting and vote. The meeting is expected to last half a day, shareholders are responsible for their own transportation and accommodation expenses.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more